CPT Overhauls Automated

Panels, HCFA To Hold Off January Startup

 

Get ready for a major shakeup of CPT organ/disease panel codes, effective January 1, 2000. The CPT editorial board has given final approval to a new automated panel for renal function, the addition of one test each to three of the existing automated panels (basic and comprehensive metabolic studies and hepatic function), and the creation of a new panel for acute hepatitis. For the three revamped automated panels, new codes have been assigned to replace those now in use. The fourth current automated panel (electrolytes, CPT 80051) remains unchanged.

 

The Health Care Financing Administration, however, is planning to delay Medicare implementation of the new and revised automated panels until at least April, though other CPT changes are expected to be adopted at the start of the new year, according to Anita Greenberg in the division of acute care.

 

Local Medicare contractors have told HCFA they will need the extra time to engineer the systems changes necessary to process the new/revised panel codes and install edits to prevent duplicate payments for panel tests. A HCFA program memorandum to carriers and intermediaries, now being drafted for release soon, is expected to instruct them not to pay claims using the new or revised automated panel codes until these have been officially adopted by the agency.

 

Some surprises: CPT 2000 incorporates a number of changes already reported by the National Intelligence Report (XX, 16/June 14, 1999,p.2), but also unfurls some new developments, most notably the creation of a new 10-test renal function panel (80069) and the elimination of existing thyroid panels 80091 and 80092. According to industry sources, the renal function panel was apparently endorsed at the request of the dialysis industry, but it is not clear who pushed to drop the thyroid panels. CPT may have done so, it is speculated, in response to comments which surfaced during the lab negotiated rulemaking marathon, question whether ordering multiple thyroid tests is consistent with “good medical practice,” in light of the increasing specificity of thyroid testing.

 

“Panel Creep”: The expansion of organ/disease panels reflects, say informed sources, the preference of physicians for the convenience of ordering tests in a panel, despite HCFA’s longstanding concern over test utilization and medical necessity. Only two years ago, at HCFA’s urging, CPT abolished the automated profile codes 80002-80019 (which had figured prominently in Operation LabScam fraud settlements throughout this decade) in favor of four smaller “clinically relevant” panels containing tests on Medicare’s national roster of automated procedures. But the agency has steadily tightened requirements for panels, in particular stipulating that for a panel to be reimbursed, all its component tests must be medically justified.

 

CPT 2000: Highlights of Changes to Lab Test Panels

 

New Panel: Renal function panel (10 automated tests) - consists of albumin, calcium, carbon dioxide, chloride, creatinine, glucose, inorganic phosphorus, potassium, sodium, and BUN.

Acute hepatitis panel - consists of Hepatitis A antibody, Hepatitis B core antibody, Hepatitis B surface antigen, and Hepatitis C antibody.

 

Revised Panels: Basic metabolic panel - calcium added to chloride, glucose, sodium, carbon dioxide, creatinine, potassium, BUN.

Comprehensive metabolic panel - Alt added to almunin, calcium, chloride, glucose, potassium, sodium, AST, total bilirubin, carbon dioxide, creatinine, alkaline phosphatase, total protein, and BUN.

 

Hepatitic function panel-Total protein added to albumin, total bilirubin, direct bilirubin, alkaline phosphatase, ALT and AST.

 

Deleted: Thyroid panel & panel with TSH; Hapatitis panel.

Source: National Intelligence Report, Vol. XXI, No. 1/Oct. 8, 1999

 

CLIENT SERVICES STARS

 

Kari Davidson has worked for Avera McKennan for 5 years, 4 of those in client services. Kari is a graduate of Washington Senior High and the MLT program at Lake Area Vo-Tech in Watertown, SD. Kari enjoys talking with and helping clients.

 

Kari has two children, Kristin 18 and Matthew 8. In her spare time she enjoys spending time with family and friends and collecting any type of pigs. She also enjoys walking, hiking, camping, and sledding.

 

FROM THE EDITOR...

 

Avera Queen of Peace has gone live with their Meditech blood bank module. This allows for easier ordering and reporting of patient results.

 

As I write this in early November, the temperatures are in the 60s and 70s. We have included some fire safety reminders in this issue. Grass fires have been a problem in much of the Midwest and remind us just how destructive fire can be. The holidays are almost upon us and house fires are often frequent once the Christmas decorations go up. Please be careful with decorations at home and work. We don’t want to loose any of our extended network family.

 

December 31, 1999 is almost upon us. Preparations for Y2K compliance are in the final stages around the Network. We’re confident that we’ll be well prepared for any problems that may arise with the coming of the millennium. Remember that 2000 is a leap year as well, and February 29 may cause some computer problems in older systems.

 

By the time you receive this Thanksgiving will have passed, and Christmas and New Year’s Day will be fast approaching. All of us at Lab News and around the network wish you and yours a safe and blessed holiday season. See you in 2000!!!

 

INFLUENZA ALERT

 

The flu season has started early this year. The first case of the year in South Dakota was detected in the week ending October 2, 1999. A 64-year old patient in Rapid City was admitted to Rapid City Regional Hospital on 9-25-99 with fever, cough, dehydration, nausea and vomiting. The patient had direct contact with a person experiencing a febrile URI who had just returned from a one-week Alaskan cruise.

 

Outbreaks of influenza were reported among tourists visiting Alaska and the Yukon Territory this summer. Influenza A H3N2 Sydney-like virus has been identified as the cause of most of these illnesses. Influenza A H3N2 Sydney-like is virus included in the vaccine for the coming year.

 

Annual vaccination is the primary method for preventing influenza. Persons who are at high risk include person 65 or older and those under 65 with chronic underlying medical conditions. Health care workers are encouraged to participate in immunization programs.

 

DID YOU KNOW…

 

Around 1000 AD, a Persian physician named Ismail of Jurjani described seven different observations made on urine: quantity, consistency, color, odor, transparency, sediment, and froth. During the Middle Ages, the great painters typically showed physicians peering into a round bottomed flask (called a matula) of urine. This practice became a common tool of quacks and charlatans, who came to be known as “Pissa Prophets.” They not only pretended to diagnose disease by visual examination of urine, but they also claimed to see into the future.

Modern Urine Chemistry Manual, Bayer Diagnostic

 

SAFETY REMINDERS

 

Here are a few reminders to help keep the upcoming holiday season safe. Remember never overload outlets, keep electrical equipment (and holiday decorations) away from water sources, check the cords on all holiday lights for damage.

 

Fire Safety: When operating a fire extinguisher remember:

   P— Pull the Pin

   A — Aim at the base of the fire

   S — Squeeze the handle

   S — Sweep across the fire’s base

 

If you discover a fire remember:

   R — Rescue anyone in danger

   A — Sound the alarm

   C — Contain the fire

   E — Extinguish the fire or evacuate

            the area

 

INFLUENZA ASSAY OFFERED AT AVERA QUEEN OF PEACE

 

Beginning Monday, November 15, Avera Queen of Peace Laboratory will begin offering Influenza testing. This procedure detects both Influenza A and B, but does not distinguish between the two.

 

The influenza assay will be done on an “as needed” basis. Sample of choice is a nasopharyngeal mini-tip swab. Throat swabs and nasal aspirates are also acceptable. (Note: Nasal washing are NOT acceptable.) Samples are stable for 24 hours at 2-8 c.

 

A good sample is essential. The nasopharyngeal and throat swabs must be vigorously rolled/rubbed against the mucosal surface. After insertion into the transport system, the ampule must NOT be broken. If the ampule is broken the test is invalidated. If a direct nasal aspirate is obtained, place it in a sterile container for transport to the lab. The sample can not be diluted with saline or water. Contact Avera Queen of Peace client services for further details on collection and transport.

 

LOCAL MEDICAL REVIEW POLICY UPDATES

 

Serum Iron Studies

Medicare Part B Model Local Medical Review Policy

     

Description: Iron studies are used in the evaluation of iron metabolism disorders, particularly iron deficiency and iron excess.

 

Iron deficiency is the most common cause of anemia. It is most often the result of blood loss but may be secondary  to iron malabsorption. Classically, serum iron is decreased in iron deficiency but is also low in acute and chronic inflammatory and neoplastic states.

 

Total iron binding capacity (TIBC ) (83550), is an indirect measurement of transferrin, a protein that binds and transports iron. It quantifies transferrin in terms of the amount of iron it can bind and is reported as percent saturation. TIBC is classically elevated in iron deficiency, pregnancy and by agents that suppress ovulation. Because transferrin levels are depressed in patients who are malnourished or who have chronic disease states, it may be normal in patients who are iron deficient.

 

Because of the significant limitations of serum iron (83540) and TIBC, serum ferritin (82728) is a more accurate measure of storage iron. Low levels are unique to iron deficiency while extremely high values are typical of iron storage disease. Many chronic inflammatory, infectious, and neoplastic diseases are characterized by moderate elevations in ferritin levels.

 

Indications and Limitations of Coverage and/or Medical Necessity:

1. Iron studies are indicated in the differential diagnosis of microcytic, hypochromic anemia as well as in iron overload conditions.

2. Frequent repeat testing is not necessary. Claims for frequent studies may result in denial or processing delays in the absence of supportive medical documentation.

3. Covered diagnosis are listed in the “Covered ICD-9 Codes” section of the model policy. It should be recognized that the medical necessity for testing will be subject to review.

4. If a normal serum ferritin level is documented, having been done for a covered sign, symptom, or disease, repeat testing would not be medically necessary unless there is a change in the patient’s condition verifying the need for repeat testing.

 

Reasons for Denial: Routine screening is not covered. Submission for ICD-9 codes not listed in model policy will be denied. Automated or manual calculations and/or extrapolated values will not be reimbursed separately.

 

Note: The mere fact of linking a covered diagnosis to a covered procedure does not support the medical necessity of the procedure. Medical Necessity of the testing must be present and documented in the ordering physician’s medical record.

Documentation Requirements: Documentation supporting the medical necessity of these tests, such as ICD-9 codes must be submitted on the claims. Failure to do so may result in denial of claim. The patient’s medical record should contain notes documenting with relevant signs/symptoms or abnormal laboratory results appropriate to the covered conditions. There must be a physician’s order for each test documented in the patient’s medical record.

 

CLARIFICATION: The August 1, 1999 Medicare A Newsline indicated that Troponin charges would be denied if any of the CK tests (82550-82554) were performed. New study information supports the need for both results to determine the underlying medical cause of chest pain. Therefore, both tests will be covered within the scope of the Troponin (84484) Local Medical Review Policy, retroactive to the policy effective date of June 21, 1999.

 

PERTUSIS IN ADULTS AND

ADOLESCENTS

 

Pertusis or whooping cough is a highly communicable respiratory disease that is traditionally seen in infants and young children. The causative agent is Bordetella pertussis. Paroxysmal cough with whoop, an elevated white blood cell count, and marked lymphocytosis are considered hallmarks of pertussis infection in children. There has been a resurgence of pertussis cases in young infants that have not been fully immunized. There is evidence to suggest that adults serve as a reservoir of infection for these children.

 

There is speculation that currently, B pertussis infections occur predominantly in adults and adolescents. Clinical manifestations in adolescents and adults differ from those seen in young children and adults; therefore, the occurrence in this population most often goes undiagnosed. Persistent cough is the most common presentation among teenagers. The perception that pertussis is only a disease of children remains among clinicians as well as members of the community. Serologic evidence of pertussis infection was demonstrated in 26% of college students with cough that lasted for seven days or longer. Similar results were obtained in a study conducted among adult patients who presented with cough as primary complaints at the Emergency Department in Vanderbilt University Hospital. Other studies also indicated that B. pertussis infections in adults were common, endemic, and rarely recognized as pertussis.

The specimen of choice to isolate B. pertussis is a nasopharyngeal swab. For maximum recovery of these organisms, two small calcium alginate or Dacron swabs on the end of a fine, flexible aluminum wire are recommended. Cotton-tip swabs should be avoided because cotton is inhibitory to the organism. To obtain adequate sampling, swabs are placed at the site for at least 30 to 60 seconds to allow organisms to be absorbed.

 

B. pertussis requires special growth culture medium. Bordet-Gengou agar has been the classic medium to recover this organism from clinical samples. In the late 1970’s Reagen-Lowe agar, a charcoal-based agar with horse blood was introduced. Numerous studies have reported its superiority over Bordet-Gengou. Regardless of the medium used, a nonselective and selective medium must be used because certain strains of B. pertussis are susceptible to methicillin or cephalexin.

Source: The Resurgence of Pertussis: the 100-Day Cough, Connie R. Mahon; Clinical Laboratory Science Sept/Oct 1999 Vol. 12/Number 5